You are here

Synergy between MAG-1 and Cyclophosphamide for Treatment of Recurrent SCLC

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA177025-01A1
Agency Tracking Number: R43CA177025
Amount: $149,819.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
115 ETNA RD, STE D
LEBANON, NH 03766-1429
United States
DUNS: 149245123
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ROY PANG
 (603) 448-5511
 roy.pang@valley.net
Business Contact
 ROY PANG
Phone: (603) 448-5511
Email: roy.pang@valley.net
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, MAG-1, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that a cancer -specific provasopressin antigen, called GRSA, present at the surface of these tumors will provide a sensitive, tumor-specific, and reliable target for the effective treatment by MAG-1 antibodies in combination with cyclophosphamide. Our preliminary data clearly show that treatment of variant SCLC tumor xenografts, with native and 90Yttrium-labelled mouse MAG-1 significantly slows growth, but this growth is almost completely impaired when antibody treatment follows cyclophosphamide. GRSA expression is a feature common to all, or most, SCLC and is absent from normal tissues. Phase 1 of this study is directed at advancing treatment of rSCLC using both mouse MAG-1 and already generated human chimeric MAG-1 a

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government